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Introduction
The purpose of this study was to perform genetic screening of the exostosin 1 (EXT1) and exostosin 2 (EXT2) genes in Cypriot patients with a clinical diagnosis of hereditary multiple osteochondromas (HMO). Initially, mutation analysis of the EXT1 gene was performed by Sanger sequencing. When no point mutation was identified in EXT1, EXT2 analysis was performed. When no sequence variant was identified in either of the candidate genes, array-comparative genomic hybridization (CGH) was implemented to detect any large copy number changes (CNCs). In total, three point mutations and a large deletion were identified in EXT1: the c.2101C>T(p.Arg701*) mutation and the ∼0.16-Mb deletion removing exons 2-11, which were previously reported whereas the c.486_489delCAGA(p.Asp162Glyfs*12) and the c.868G>T(p.Glu290*) mutations which were novel. It is the first report on genetic screening of five HMO patients of Cypriot descent. The observations presented provide additional evidence for the variability in phenotypic expression and the mutational spectrum of this disorder.
The term HMO, or hereditary multiple exostoses (HME), MIM: 133700 and MIM: 133701 respectively is used to describe a genetic disorder characterized by the development of multiple, circumscript, occasionally painful and usually symmetric bony protuberances called osteochondromas (benign cartilaginous tumours which most frequently grow outward from the juxtaphyseal region of the long bones or * For correspondence. E-mail: gtanteles@cing.ac.cy. the surface of flat bones). With advancing age, osteochondromas grow in size and number until the completion of skeletal maturity by which time no new ones tend to be observed. HMO can, beside other problems, lead to a reduction in skeletal growth, secondary bony deformities, restricted joint motion, short stature and compression of peripheral nerves (reviewed extensively in Hennekam 1991; Wuyts et al. 1993; updated 21 Nov. 2013) . Major radiographic features, include irregular expansion of the metaphyses of the long bones with outgrowths projecting from the sides of the expanded areas, multiple exostoses of the flat bones or jutting from relatively normal diaphysis and secondary bony deformities. The risk for malignant transformation (typically osteochondrosarcoma) increases with age, although the lifetime risk in most studies seems to be low (Legeai-Mallet et al. 1997) . However, in certain families (Porter et al. 2004; Vujic et al. 2004) , and a large study in 2011 by Pedrini et al. (2011) , the rate of malignant transformation was calculated to be as high as 5-6%. HMO is inherited in an autosomal dominant manner, having an estimated penetrance of ∼96% in females and 100% in males, and displays great interfamilial and intrafamilial variability in phenotypic expression. Mutations in either the EXT1 gene on chromosome 8q24.11 or the EXT2 gene on 11p11.2 have been shown to cause HMO accounting for ∼60-70% and 20-30% of cases, respectively.
The purpose of this study was to identify mutations in either of the EXT gene loci (EXT1 initially and subsequently EXT2 in those having no EXT1 pathogenic variants) in Cypriot patients with a clinical diagnosis of HMO. Five patients, representing the first report of genetic screening of HMO affected individuals in the Cypriot population are described.
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Material and methods

Patients
This study included five patients (from four families) who were enrolled at our outpatient clinic and reviewed by a clinical geneticist. The diagnosis of HMO was suspected on the basis of clinical examination and presence of multiple osteochondromas (at least three or more) confirmed by xrays. Peripheral blood samples were collected and patient's genomic DNA was sent to our laboratories initially for EXT1 sequencing. If no EXT1 mutations were identified, the EXT2 gene was subsequently sequenced. Where required, array-CGH analysis was also performed to assess for copy number changes. Whenever possible, analysis was also carried out on samples from the HMO patient's parents in an attempt to establish whether the identified mutations were inherited or had occurred as de novo events. All study participants tested provided an informed written consent.
DNA amplification
Genomic DNA was extracted from peripheral blood using the QiagenQIAmp DNA Blood Midi Kit (Qiagen, Valencia, USA). Mutation analysis of all the coding regions of the human EXT1 and EXT2 genes was performed using intronic primers and optimized PCR conditions (available upon request).
DNA analysis
Direct sequencing of the EXT genes was performed on an ABI 3130xl apparatus (Applied Biosystems, Foster City, USA) according to manufacturer's procedures. Where no EXT1/EXT2 sequence variants were identified, array-CGH analysis was performed using Cytochip ISCA array (BlueGnome ver. 1.0) with 180,000 oligos according to manufacturer's recommendations. The array was scanned in a 5 μm resolution using the Agilent DNA microarray scanner (Agilent Technologies, Santa Clara, USA) and fluorescent ratios were calculated using the BlueFuse Multi software (BlueGnome, Cambridge, UK).
Results
Five patients with clinical and radiological evidence of multiple exostoses were selected for genetic screening as described earlier in materials and methods. Patient 1 presented to Clinical Genetics at the age of 32 years. She reported an history of metaphyseal widening apparently having been identified following an injury at the age of 14 years. She was initially diagnosed with Pyle disease. She had a long-standing history of troublesome joint aches and pains, and unilateral hearing loss (figure 1, a and b). Her mother (patient 2), was initially assessed at the age of 60 years. She had an history of multiple bony exostoses and radiological evidence suggestive of HMO. Patient 3 presented to Clinical Genetics at the age of 3 years and 4 months, history of ankle swelling which prompted further evaluation by x-rays which revealed multiple exostoses involving both upper and lower limbs and widening of the metaphyses (figure 1c). In addition to the exostoses she had lumbar lordosis. Patient 4 was clinically diagnosed with HMO at the age of 2 years and 6 months after the identification of bony lumps around the knees. He went on to develop numerous exostoses at several sites and underwent various operations for removal of large osteochondromas. He had significant bony deformities, scoliosis and restricted height. Patient 5 had a family and a personal history of HMO with radiological evidence of multiple exostoses. He had minor symptoms, but his son (not available for testing) was described as being severely affected. A summary of the patients' clinical and molecular characteristics is provided in table 1. Point mutations or deletions involving the EXT1 gene were detected in all five patients (table 1) . No EXT2 mutations were identified in this cohort.
EXT1 point mutations
An EXT1 point mutation (c.2101C>T) was identified in two related female patients (patients 1 and 2; daughter and mother respectively, figure 2a ). This is a nonsense mutation, reported previously by Seki and colleagues (Seki et al. 2001) , which results in a premature stop codon in exon 11 (p.Arg701*) of this gene.
The novel mutation c.868G>T(p.Glu290*) in exon 1 of the EXT1 gene introducing a stop codon was identified in patient 3. Mutation analysis of the parents did not reveal the same mutation identified in their daughter (figure 2b).
EXT1 deletions
Sequence analysis of the EXT1 gene in patient 4 identified no genetic alterations. Consequently, the EXT2 gene (the second most common disease-causing locus for HMO) was analysed but revealed no mutations either. To rule out any copy number changes, array-CGH analysis involving either EXT1 or EXT2 locus was performed identifying a previously reported (Seki et al. 2001; Szuhai et al. 2011 ) intragenic EXT1 deletion of exons 2 to 11 (figure 2c).
In addition, a novel 4-bp deletion, c.486_489delCAGA (p.Asp162Glyfs*12) was identified in a male patient (patient 5) within the coding region of exon 1 of the EXT1 gene (figure 2d).
Discussion
Both EXT1 and EXT2 code for glycosyltransferases involved in the polymerization of heparan sulphate (McCormick et al. 1998 (McCormick et al. , 2000 which in turn affects downstream signalling, important in the regulation of chondrocyte proliferation (Bellaiche et al. 1998) . There is evidence pointing towards an EXT1 and EXT2 tumour suppressor activity and a 'two-hit' hypothesis model has been proposed for the development of osteochondromas, due to the observed loss of heterozygosity in chondrosarcomas (Hecht et al. 1997; Bovee et al. 1999 ) and the presence of homozygous EXT1 deletions in solitary osteochondromas (Hameetman et al. 2007 ). More than 400 pathogenic variants have been described in EXT1 according to MOdb (http://medgen. ua.ac.be/LOVDv.2.0/home.php), Multiple Osteochondromas Mutation Database (Jennes et al. 2009 ). Most of the reported mutations seem to be 'private' and are dispersed throughout the entire gene. Most EXT1/EXT2 mutations are inactivating (nonsense, frameshift or splice-site) and are predicted to result in premature termination of translation. The remaining mutations are usually missense (Wuyts et al. 1993 updated 21 Nov. 2013 Park et al. 1999; Xu et al. 1999; Jennes et al. 2009 ). In the present study, a nonsense mutation in exon 11 (p.Arg701*) of the EXT1 gene was detected in patients 1 and 2 (figure 2a) . This mutation has previously been reported in other HMO patients (Seki et al. 2001 ). According to MOdb, an additional eight, exon 11, EXT1 mutations have been reported. Four of them involve deletions leading to frameshift and an additional four are nonsense mutations. This suggests that exon 11 of the EXT1 might be a mutational hotspot.
In patient 3, sequence analysis of the EXT1 gene identified the c.868G>T (p.Glu290*) mutation ( figure 2B ). This alteration is predicted to result in premature termination of the gene product in exon 1. The c.868G>T mutation has not been reported previously on MOdb. Mutation analysis of both parents revealed that the mutation had occurred as a de novo event in the proband. Approximately 10% of HMO cases reported have a de novo mutation in either of the EXT genes (Wuyts et al. 1993 updated Nov. 21 2013 .
Several mechanisms have been implicated in the generation of recurrent or nonrecurrent, disease-associated genomic rearrangements such as nonallelic homologous recombination (NAHR), nonhomologous endjoining (NHEJ) and fork stalling and template switching (FosTeS) (Gu et al. 2008) . More specifically, it has been shown that in HMO patients, both NAHR which is mediated by Alu-sequences as well as NHEJ are causal and that these deletions seem to be nonrecurring .
Intragenic deletions involving single or multiple EXT1 or EXT2 exons are found in ∼10% of tested patients (Vink et al. 2005; Jennes et al. 2009 ). In the current study, patient 4 was found to have an intragenic EXT1 deletion of ∼0.16 Mb removing exons 2 to 11. Similar deletions have previously been reported in several patients either in constitutional or mosaic forms (Jennes et al. 2008 Szuhai et al. 2011; Sarrion et al. 2013) . In 2011, a study by Jennes et al. demonstrated that the EXT1 breakpoints of a deletion involving exons 2 to 11 were located within a 5-bp homologous sequence. Multiple long interspersed element-1 (LINE1) and Alu elements were identified at the distal breakpoint, while at the proximal breakpoint the complement of a deletion hotspot consensus sequence was present ). In addition, there are reports of patients with similar deletions manifesting signs and symptoms even if the deletion was present in a mosaic form Sarrion et al. 2013) leading to the suggestion that deletion of a single allele even in a relatively small number of cells as in the case of somatic mosaicism is sufficient enough to trigger the phenotype.
In the case reported in the current study, the large EXT1 deletion of exons 2 to 11 was identified by array-CGH. We were unable to obtain parental samples to confirm whether this deletion was inherited or was the result of a de novo event, but there were reports of the patient's mother also being affected (not evaluated in clinic). It remains unclear whether on a DNA sequence level the breakpoints in our patient are similar to the ones previously reported. Exon 1 is the largest EXT1 exon and codes for more than 40% of the EXT1 protein (Vink et al. 2005) . The 4-bp deletion in exon 1 of the EXT1 gene presented here has not, to our knowledge, been previously reported and can be considered pathogenic as it most probably leads to protein truncation.
Several reports have shown a relation between EXT1 or EXT2 mutations and the severity of HMO, with the most severe forms of the disease being associated with EXT1 mutations (Francannet et al. 2001; Porter et al. 2004; Alvarez et al. 2006; Pedrini et al. 2011) . The development of HMO was associated with EXT1 mutations in all patients presented in our study. There was clear evidence of variability in phenotypic expression. Limitations due to a small sample size which do not allow us to draw definitive conclusions but should further enrich available data on genotype-phenotype correlations.
This is the first report of molecularly confirmed HMO patients of Cypriot descent. The observations presented in this report provide additional evidence for the rich variability in phenotypic expression, the mutational heterogeneity and ethnic diversity associated with this condition.
